Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy

Ironwood Pharmaceuticals' stock is a buy based on the potential success of its second apraglutide trial.

The trial is expected to read out in the first half of 2023.

Analysts believe the stock has significant upside potential if the trial is successful.